These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities. Abdellatif KR; Chowdhury MA; Dong Y; Knaus EE Bioorg Med Chem; 2008 Jul; 16(13):6528-34. PubMed ID: 18513975 [TBL] [Abstract][Full Text] [Related]
6. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies. Abdellatif KR; Chowdhury MA; Dong Y; Velázquez C; Das D; Suresh MR; Knaus EE Bioorg Med Chem; 2008 Nov; 16(22):9694-8. PubMed ID: 18930406 [TBL] [Abstract][Full Text] [Related]
7. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies. Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez CA; Suresh MR; Knaus EE Bioorg Med Chem Lett; 2009 Jun; 19(11):3014-8. PubMed ID: 19419861 [TBL] [Abstract][Full Text] [Related]
8. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies. Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez C; Suresh MR; Knaus EE Bioorg Med Chem; 2009 Jul; 17(14):5182-8. PubMed ID: 19500994 [TBL] [Abstract][Full Text] [Related]
9. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice. Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. Alhashimi RT; Ghatge MS; Donkor AK; Deshpande TM; Anabaraonye N; Alramadhani D; Danso-Danquah R; Huang B; Zhang Y; Musayev FN; Abdulmalik O; Safo MK Biomolecules; 2022 May; 12(5):. PubMed ID: 35625623 [TBL] [Abstract][Full Text] [Related]
11. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy. Steffen RP; Liard JF; Gerber MJ; Hoffman SJ Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327 [TBL] [Abstract][Full Text] [Related]
13. Permeability changes in response to NONOate and NONOate prodrug derived nitric oxide in a blood-brain barrier model formed by primary porcine endothelial cells. Winter S; Konter J; Scheler S; Lehmann J; Fahr A Nitric Oxide; 2008 May; 18(3):229-39. PubMed ID: 18284923 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies. Kaur J; Bhardwaj A; Huang Z; Narang D; Chen TY; Plane F; Knaus EE J Med Chem; 2012 Sep; 55(17):7883-91. PubMed ID: 22916833 [TBL] [Abstract][Full Text] [Related]
15. Allosteric modification of oxygen delivery by hemoglobin. Wahr JA; Gerber M; Venitz J; Baliga N Anesth Analg; 2001 Mar; 92(3):615-20. PubMed ID: 11226087 [TBL] [Abstract][Full Text] [Related]
16. Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry. Yi R; Sandhu J; Zhao S; Lam G; Loganathan D; Morrissey B J Mass Spectrom; 2014 Jan; 49(1):57-67. PubMed ID: 24446264 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Amorino GP; Lee H; Holburn GE; Paschal CB; Hercules SK; Shyr Y; Steffen RP; Choy H Radiat Res; 2001 Sep; 156(3):294-300. PubMed ID: 11500138 [TBL] [Abstract][Full Text] [Related]
18. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Grinberg OY; Miyake M; Hou H; Steffen RP; Swartz HM Adv Exp Med Biol; 2003; 530():287-96. PubMed ID: 14562725 [TBL] [Abstract][Full Text] [Related]
19. A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies. Abdellatif KR; Huang Z; Chowdhury MA; Kaufman S; Knaus EE Bioorg Med Chem Lett; 2011 Jul; 21(13):3951-6. PubMed ID: 21641217 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of chiral allosteric modifiers of hemoglobin. Phelps Grella M; Danso-Danquah R; Safo MK; Joshi GS; Kister J; Marden M; Hoffman SJ; Abraham DJ J Med Chem; 2000 Dec; 43(25):4726-37. PubMed ID: 11123981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]